Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

TD Cowen adjusted its outlook on Regeneron Pharmaceuticals, with analyst Tyler Van Buren revising the price target to $1,030 ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...

Police figures obtained by road safety charity IAM RoadSmart indicate 51% of tests were positive in 2023, and 49% were positive in the first seven months of last year. This is based on data provided ...

That may yet prove fanciful, but a positive result in the Theatre of Dreams is not beyond them if they can hit the heights of Nice and United cannot muster a better showing than they offered in ...

To avoid this, anger must align with a vision for positive change. It must remain grounded in purpose and guided by reason, compassion, and an unwavering commitment to the greater good.

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...